Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053484 | 0.85 | LMNA (0.45) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL2097553 | 0.81 | ALDH1A1 (0.43) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL8925134 | 0.81 | NPC1 (0.51) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL18496481 | 0.80 | ALDH1A1 (0.53) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL4403732 | 0.79 | P2RX7 (0.81) | LMNAP2RX7ALDH1A1KMT2A | |
| SCHEMBL10022378 | 0.79 | HDAC1 (0.42) | LMNAP2RX7ALDH1A1TSHRHRH3 | |
| SCHEMBL19732308 | 0.79 | ALDH1A1 (0.54) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL4408444 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL2163180 | 0.78 | LMNA (0.59) | LMNAP2RX7ALDH1A1KMT2AMEN1 | |
| SCHEMBL156417 | 0.78 | ALDH1A1 (0.66) | LMNAP2RX7ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-11-16 | — | — | US | disclosed |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-11-16 | — | — | US | disclosed |
| WO-2021231553-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2020123670-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007125398-A2 | : SULFONAMIDE COMPOUNDS AS ANTAGONISTS OF THE N-TYPE CALCIUM CHANNEL | PFIZER JAPAN INC. (JP) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| US-4632674-A | Diesel fuel containing a tetrazole or triazole cetane improver | EXXON CHEMICAL PATENTS INC. (US) | 1986-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | LMNA 4121/4885P2RX7 1585/4885ALDH1A1 4677/4885 |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | CACNA1G, CACNA1I, CACNG3 | LMNA 1895/4885P2RX7 184/4885ALDH1A1 3418/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | LMNA 4289/4885P2RX7 1388/4885ALDH1A1 4769/4885 |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | LMNA 1762/4885P2RX7 4192/4885ALDH1A1 4081/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | LMNA 1091/4885P2RX7 1100/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.